Trial Profile
A two-arm, randomised, assessor-blind, parallel group study to evaluate the effect of fluticasone/formoterol breath actuated inhaler (BAI) and Relvar Ellipta DPI on ventilation heterogeneity in subjects with partially controlled or uncontrolled asthma.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Formoterol/fluticasone propionate (Primary) ; Vilanterol/fluticasone furoate
- Indications Asthma
- Focus Therapeutic Use
- Sponsors Mundipharma Research
- 18 Aug 2017 Status changed from active, no longer recruiting to completed.
- 18 Jul 2017 Status changed from recruiting to active, no longer recruiting.
- 01 Aug 2016 Status changed from not yet recruiting to recruiting.